In the coming 10 years TBVI hopes to raise 200 million euros from governments, foundations and private industry for the discovery and early clinical development of new vaccines. Development of new vaccines is crucial because the only existing vaccine, BCG, is not very effective in young adults, the group of people mostly affected by the disease.
“New vaccines are essential to achieve the international aim of a TB-free world in 2050. We need several types, not only for initial protection against TB, but also to boost adolescent immunity and prevent disease in latently infected individuals,” explains Jelle Thole, director of TBVI. “To enable development of these vaccines, more investment is needed.”
TBVI financially and practically supports and facilitates a growing international network of over thirty universities, institutes and industries involved in research and development of new TB vaccines. The organization evolved from TBVAC, a European Union (EU) funded project to identify good candidates for new TB vaccines. TBVAC has yielded five new TB vaccine candidates, fifteen candidate biomarkers and three candidate adjuvant molecules. These hopeful candidates are now in preclinical development or even clinical phase.
TBVI is extremely pleased with the encouraging new signs of progress on TB. “Because of this funding, we can continue to change new discoveries into real vaccines,” says Joris Vandeputte, senior vice president Fundraising & Advocacy at TBVI. “These vaccines are urgently needed, as the resurrection of TB is a ticking time bomb. Many people believe it is a disease of the past, but in fact it is endangering our future, taking almost 1.8 million lives a year.”
The global burden of TB is slowly falling, but still two billion people, about one third of the world’s population, are estimated to be infected with the mycobacteria that cause TB. Most of them develop a latent infection, with about a 10 percent risk of developing the infectious disease later in life. People with HIV are 20 times more likely to develop the symptoms once they are infected. Efficient drugs to treat TB are available, but involve a long and burdensome treatment period of up to a year. Additionally, worldwide prevalence of various forms of drug-resistant TB poses an increasing problem and enormous challenges to effective treatment.
With new infections occurring at a rate of one per second, millions of people develop TB symptoms every year. In 2007, there were 9.27 million new cases. 500,000 of those were multi-drug resistant and 50,000 of those were extensively drug resistant (source: World Health Organization).
Innovation Award of the United Nations Environment Programme for PhD Student from ZMT
22.03.2018 | Leibniz-Zentrum für Marine Tropenforschung (ZMT)
ERC Project set to boost application of adhesive structures
19.03.2018 | INM - Leibniz-Institut für Neue Materialien gGmbH
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences